Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda

Ashwani K. Singal, Krishna V.R. Venkata, Sarat Jampana, Fakhar Ul Islam, Karl Anderson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Experience on HCV treatment in patients with PCT is limited. Recently, HCV treatment has improved with direct-acting antivirals (DAA). We review our experience on HCV treatment in patients with PCT with older and newer regimens. Materials and Methods A retrospective chart review was conducted. HCV treatment was attempted 22 times in 13 patients with PCT (5 attempts in 1, 2 in 5 and 1 in the other 7 patients). Results Before starting HCV treatment, PCT was in complete remission in 16, partial remission in 2, unknown status in 2 and active in 2 instances. PCT relapsed during therapy 6 times (all interferon-based regimens and 2 including telaprevir), 4 requiring treatment interruption. Treatment was interrupted for reasons other than PCT relapse in 2 patients treated with interferon-based regimens. To prevent PCT recurrence, hydroxychloroquine was continued during HCV therapy 6 times (3 interferon regimens, 2 ribavirin regimens without interferon and 1 DAA alone). Twelve patients achieved sustained viral response, 3 with interferon regimens and 9 with DAA. Two patients with active PCT were treated with DAA, with reduction of plasma porphyrins in 1 and normalization in the other at the end of HCV therapy. Conclusions HCV treatment regimens including interferon or ribavirin may precipitate PCT relapse. Hydroxychloroquine may be useful to prevent such relapses. In this limited experience, DAA were not associated with PCT relapse. Studies are needed to examine DAA as a primary PCT treatment in HCV-infected patients.

Original languageEnglish (US)
Pages (from-to)523-528
Number of pages6
JournalAmerican Journal of the Medical Sciences
Volume353
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Porphyria Cutanea Tarda
Hepatitis C
Hepacivirus
Interferons
Antiviral Agents
Recurrence
Therapeutics
Hydroxychloroquine
Ribavirin
Porphyrins
Virus Diseases

Keywords

  • Direct-acting antivirals
  • Hepatitis C
  • Interferon
  • Porphyria

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda. / Singal, Ashwani K.; Venkata, Krishna V.R.; Jampana, Sarat; Islam, Fakhar Ul; Anderson, Karl.

In: American Journal of the Medical Sciences, Vol. 353, No. 6, 01.06.2017, p. 523-528.

Research output: Contribution to journalArticle

Singal, Ashwani K. ; Venkata, Krishna V.R. ; Jampana, Sarat ; Islam, Fakhar Ul ; Anderson, Karl. / Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda. In: American Journal of the Medical Sciences. 2017 ; Vol. 353, No. 6. pp. 523-528.
@article{21ca47a03a75452aa10e6765a6c8c5fa,
title = "Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda",
abstract = "Background Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Experience on HCV treatment in patients with PCT is limited. Recently, HCV treatment has improved with direct-acting antivirals (DAA). We review our experience on HCV treatment in patients with PCT with older and newer regimens. Materials and Methods A retrospective chart review was conducted. HCV treatment was attempted 22 times in 13 patients with PCT (5 attempts in 1, 2 in 5 and 1 in the other 7 patients). Results Before starting HCV treatment, PCT was in complete remission in 16, partial remission in 2, unknown status in 2 and active in 2 instances. PCT relapsed during therapy 6 times (all interferon-based regimens and 2 including telaprevir), 4 requiring treatment interruption. Treatment was interrupted for reasons other than PCT relapse in 2 patients treated with interferon-based regimens. To prevent PCT recurrence, hydroxychloroquine was continued during HCV therapy 6 times (3 interferon regimens, 2 ribavirin regimens without interferon and 1 DAA alone). Twelve patients achieved sustained viral response, 3 with interferon regimens and 9 with DAA. Two patients with active PCT were treated with DAA, with reduction of plasma porphyrins in 1 and normalization in the other at the end of HCV therapy. Conclusions HCV treatment regimens including interferon or ribavirin may precipitate PCT relapse. Hydroxychloroquine may be useful to prevent such relapses. In this limited experience, DAA were not associated with PCT relapse. Studies are needed to examine DAA as a primary PCT treatment in HCV-infected patients.",
keywords = "Direct-acting antivirals, Hepatitis C, Interferon, Porphyria",
author = "Singal, {Ashwani K.} and Venkata, {Krishna V.R.} and Sarat Jampana and Islam, {Fakhar Ul} and Karl Anderson",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.amjms.2017.03.007",
language = "English (US)",
volume = "353",
pages = "523--528",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda

AU - Singal, Ashwani K.

AU - Venkata, Krishna V.R.

AU - Jampana, Sarat

AU - Islam, Fakhar Ul

AU - Anderson, Karl

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Experience on HCV treatment in patients with PCT is limited. Recently, HCV treatment has improved with direct-acting antivirals (DAA). We review our experience on HCV treatment in patients with PCT with older and newer regimens. Materials and Methods A retrospective chart review was conducted. HCV treatment was attempted 22 times in 13 patients with PCT (5 attempts in 1, 2 in 5 and 1 in the other 7 patients). Results Before starting HCV treatment, PCT was in complete remission in 16, partial remission in 2, unknown status in 2 and active in 2 instances. PCT relapsed during therapy 6 times (all interferon-based regimens and 2 including telaprevir), 4 requiring treatment interruption. Treatment was interrupted for reasons other than PCT relapse in 2 patients treated with interferon-based regimens. To prevent PCT recurrence, hydroxychloroquine was continued during HCV therapy 6 times (3 interferon regimens, 2 ribavirin regimens without interferon and 1 DAA alone). Twelve patients achieved sustained viral response, 3 with interferon regimens and 9 with DAA. Two patients with active PCT were treated with DAA, with reduction of plasma porphyrins in 1 and normalization in the other at the end of HCV therapy. Conclusions HCV treatment regimens including interferon or ribavirin may precipitate PCT relapse. Hydroxychloroquine may be useful to prevent such relapses. In this limited experience, DAA were not associated with PCT relapse. Studies are needed to examine DAA as a primary PCT treatment in HCV-infected patients.

AB - Background Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Experience on HCV treatment in patients with PCT is limited. Recently, HCV treatment has improved with direct-acting antivirals (DAA). We review our experience on HCV treatment in patients with PCT with older and newer regimens. Materials and Methods A retrospective chart review was conducted. HCV treatment was attempted 22 times in 13 patients with PCT (5 attempts in 1, 2 in 5 and 1 in the other 7 patients). Results Before starting HCV treatment, PCT was in complete remission in 16, partial remission in 2, unknown status in 2 and active in 2 instances. PCT relapsed during therapy 6 times (all interferon-based regimens and 2 including telaprevir), 4 requiring treatment interruption. Treatment was interrupted for reasons other than PCT relapse in 2 patients treated with interferon-based regimens. To prevent PCT recurrence, hydroxychloroquine was continued during HCV therapy 6 times (3 interferon regimens, 2 ribavirin regimens without interferon and 1 DAA alone). Twelve patients achieved sustained viral response, 3 with interferon regimens and 9 with DAA. Two patients with active PCT were treated with DAA, with reduction of plasma porphyrins in 1 and normalization in the other at the end of HCV therapy. Conclusions HCV treatment regimens including interferon or ribavirin may precipitate PCT relapse. Hydroxychloroquine may be useful to prevent such relapses. In this limited experience, DAA were not associated with PCT relapse. Studies are needed to examine DAA as a primary PCT treatment in HCV-infected patients.

KW - Direct-acting antivirals

KW - Hepatitis C

KW - Interferon

KW - Porphyria

UR - http://www.scopus.com/inward/record.url?scp=85021859632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021859632&partnerID=8YFLogxK

U2 - 10.1016/j.amjms.2017.03.007

DO - 10.1016/j.amjms.2017.03.007

M3 - Article

VL - 353

SP - 523

EP - 528

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 6

ER -